Results 141 to 150 of about 681,792 (231)

Novel Bicyclic Heterocycles as FGFR Inhibitors for Treating Cancer. [PDF]

ACS Med Chem Lett, 2021
Sabnis RW.
europepmc   +1 more source

Dilution‐Driven Regulation of Biostimulatory Signaling in Calcium Hydroxylapatite–PRGF Systems: Implications for Early Dermal Remodeling

Journal of Cosmetic Dermatology, Volume 25, Issue 11, November 2026.
ABSTRACT Background Calcium hydroxylapatite (CaHA)‐based fillers act as both volumizing agents and bioactive scaffolds capable of inducing matrix synthesis and dermal remodeling. Their rheological properties and biological activity can be modulated via dilution strategies, expanding their applicability in regenerative and aesthetic medicine.
Eduardo Anitua, Roberto Tierno, Mohammad Hamdan Alkhraisat   +2 more
wiley   +1 more source

Early‐Life Betaine Supplementation Drives Sex‐Specific Metabolic Programming in Rats, Affecting FGF21 Signaling and Energy Balance

The FASEB Journal, Volume 40, Issue 20, 31 October 2026.
A maternal western diet (WD) and betaine supplementation during suckling influence metabolic programming. A maternal WD induced adverse metabolic effects in offspring, accompanied by altered FGF21‐related gene expression and decreased Akkermansia muciniphila abundance.
Rocío A. Martín‐Chamorro, Catalina A. Pomar, Andreu Palou, Catalina Picó, Ana M. Rodríguez   +4 more
wiley   +1 more source

Diethylene Glycol‐Linked Ring‐Fused Bis‐Azoles: Target‐Oriented Synthesis, In Silico Screening, and Antitumor Activity

ChemMedChem, Volume 21, Issue 19, 14 October 2026.
A series of diethylene glycol‐linked cyclic derivatives with diversity in the heterocyclic motif have been synthesized and screened for antitumor activity. Two bis‐thiazolo[3,2‐a]pyrimidinone derivatives displayed moderate cytotoxicity, high selectivity against hepatocellular carcinoma cells, promising VEGFR2, and remarkable FGFR2 inhibitory activities
Sami A. Al‐Hussain, Abdulrahman S. Alharbi, Zeinab A. Muhammad, Alyaa S. Abdel Halim, Magdi E. A. Zaki, Mark C. Bagley, Refaie M. Kassab   +6 more
wiley   +1 more source

Clinical response to FGFR inhibitors in patients with FGFR2-amplified advanced gastric cancer: two case reports. [PDF]

Front Oncol
Li JJ, Qian Y, Xu HT, Nie YL.
europepmc   +1 more source

Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines. [PDF]

Int J Oncol, 2021
Holzhauser S, Lukoseviciute M, Papachristofi C, Vasilopoulou C, Herold N, Wickström M, Kostopoulou ON, Dalianis T.   +7 more
europepmc   +1 more source

Healthy Participant Versus Patient Selection for Clinical Pharmacology Studies in Small‐Molecule Oncology Drug Development

Clinical and Translational Science, Volume 19, Issue 11, November 2026.
Paridhi Gupta, Zheyi Hu, Li Zhu, Lora Hamuro   +3 more
wiley   +1 more source

FGFR inhibitors in cholangiocarcinoma: what's now and what's next? [PDF]

Ther Adv Med Oncol, 2020
Saborowski A, Lehmann U, Vogel A.
europepmc   +1 more source

Design, synthesis and biological evaluation of pyrazolo[3,4-d]pyridazinone derivatives as covalent FGFR inhibitors. [PDF]

Acta Pharm Sin B, 2021
Wu X, Dai M, Cui R, Wang Y, Li C, Peng X, Zhao J, Wang B, Dai Y, Feng D, Yang T, Jiang H, Geng M, Ai J, Zheng M, Liu H.   +15 more
europepmc   +1 more source

FGF/FGFR inhibitors downmodulates c-Myc oncoprotein and hampers the growth of adrenocortical carcinoma

: Adrenocortical carcinoma (ACC) is a rare endocrine neoplastic disease that originates from the cortical cortex of adrenal gland. Unfortunately, after complete resection of the tumor, ACC relapses either locally or with distant metastasis in about 74 ...
Taranto, Sara, Faletti, Jessica, Turati, Marta, Rocca, Edoardo, Laganà, Marta, Abate, Andrea, Mignani, Luca, Gazzaroli, Giorgia, Presta, Marco, Tamburello, Mariangela, Garattini, Giulia, Ronca, Roberto, Giacomini, Arianna, Sigala, Sandra, Hantel, Constanze, Castelli, Riccardo, Turati M., Tamburello M., Ronca R., Gazzaroli G., Presta M., Faletti J., Hantel C., Taranto S., Rocca E., Sigala S., Castelli R., Garattini G., Abate A., Mignani L., Lagana M., Giacomini A.   +31 more
core   +1 more source